Home › Gestational Diabetes › NCT06184373
Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot
Early Investigation of Glucose Monitoring After Gestational Diabetes (ENGAGED): Utility and Acceptability of Continuous Glucose Monitoring in the Early Postpartum Period After Gestational Diabetes Mellitus
Who can join
Ages 18 to 50 · Women · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Women with a viable singleton intrauterine pregnancy * Able to understand the study, and having understood, provide written informed consent in English * Recent pregnancy affected by gestational diabetes Exclusion Criteria: * Pregestational Diabetes (Type I or Type II) * Continued use of diabetes medications (including metformin and insulin) immediately after delivery * Preterm delivery (\< 37 weeks gestation) * Twin or higher order gestation * No access to a smartphone * Unable or unwilling to wear CGM or return for follow up at postpartum mother-infant dyad clinic * Participation in this trial in a prior pregnancy * History of skin allergy to adhesive products or CGM
About the study
One third of women with gestational diabetes (GDM), diabetes diagnosed during pregnancy, have abnormal glucose levels within 3 years after pregnancy, but follow up is low. Continuous glucose monitors (CGM), a small sensor inserted under the skin, may be able to screen women with GDM for diabetes risk. The investigators will ask postpartum women to use CGM at 6-8 weeks postpartum and answer surveys about quality of life after wearing the CGM. The investigators will collect data on blood glucose trends for future studies if participants find CGM use acceptable. The investigators hope to learn if CGM could improve postpartum follow up experiences for people with recent GDM.
What is being tested
- Continuous glucose monitor (device)
- Oral Glucose Tolerance Test (diagnostic test)
- Hemoglobin A1c (diagnostic test)
Sponsor: Ohio State University · Participants: 20 · Started: Jun 6, 2025
Contact the study team
- Rachel Gordon, MD, MPH · Phone: 614-293-7980
- Seuli Brill, MD · Phone: 614-293-7980
Official record on ClinicalTrials.gov — NCT06184373
Locations in the U.S.
| Ohio | Ohio State University Medical Center, Columbus |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.